Effectiveness and safety of azvudine versus nirmatrelvir/ritonavir in hospitalized patients with COVID-19

BMC Infectious Diseases

Table 4 Secondary endpoints of the efficacy of two groups

	Azvudine(n = 521)	Paxlovid(n = 207)	P value	FDR P
HFNC (n, %)	42(8.1)	27(13.0)	0.054	0.483
NIMV (n, %)	25(4.8)	13(6.3)	0.531	0.884
IMV (n, %)	41(7.9)	19(9.2)	0.667	0.884
Disease progression (n, %)	71(13.6)	32(15.5)	0.602	0.884
Hospital length of stay (d), median[IQR]	13.0[8.0,19.0]	12.0[9.0,19.5]	0.884	0.884
Time to fever resolution (d), median[IQR]	127	59
	3.0[2.0,5.0]	3.0[1.0,6.0]	0.547	0.884
Duration of IMV (d), median[IQR]	41	19
	17.0[8.0,24.0]	12.0[8.5,21.0]	0.732	0.884

HFNC, high-flow nasal cannula; NIMV, non-invasive mechanical ventilation; IMV, invasive mechanical ventilation; IQR, interquartile ranges; FDR, false discovery rate

ISSN: 1471-2334